Hints and tips:
Related Special Reports
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...GIC took a 25 per cent stake in CitizenM five years ago in a deal that valued the business at €2bn including debt....
...A sharper focus on operations is a crucial part of efforts by activist investors to put the gambling group in a position where it could ultimately be sold or broken up....
...A small number of people in equities are trialling a rival offering from US data and software company FactSet, which costs about a third of the price, one of the people said....
...the sale if a buyer is found....
...He says Vertex’s $4.8bn R&D budget is not about maximising “shots on goal”; it is instead focused on “a set number” of diseases where Vertex has “super-high conviction that they’re going to work”....
...Biogen posted higher than expected profits in the first quarter as a $1bn cost-cutting drive began to pay off, but sales of its novel Alzheimer’s drug Leqembi lagged behind expectations....
...Pfizer is gearing up to launch its first-ever gene therapy at a list price of $3.5mn, after US regulators approved the treatment for a rare blood clotting disorder on Friday....
...A US senate committee chaired by Bernie Sanders has launched an investigation into the steep prices charged by Novo Nordisk for its blockbuster diabetes and anti-obesity medications Ozempic and Wegovy....
...A spokesperson for China’s Ministry of Foreign Affairs said: “China is a country ruled by law. All Chinese law enforcement and judicial activities are carried out based on facts and the law....
...Along with striking a co-brand deal with CVS to offer Hyrimoz at a discounted price of $1,315 a month, Sandoz has a higher list price version of the biosimilar, priced similarly to Humira at more than $6,000...
...McKinsey is facing a criminal investigation in the US over its work for opioid manufacturers, piling new pressure on a firm that has paid almost $1bn to settle civil claims that its advice fed an epidemic...
...“That’s what we do as a leadership team . . . is ensuring that we have back-up supply if there are any issues, regardless if it’s a regulatory issue or if it’s a natural disaster or if it’s some sort of...
...A blood test to detect amyloid beta fragments, removing the need for a $5,000 PET scan, is commercially available but not widely used....
...The health insurer said it recorded a net loss of around $1.53 a share in the three months to the end of March, compared with a profit of $5.95 a share during the same period last year....
...Joaquin Duato, J&J’s chief executive, said the acquisition “provides a unique opportunity to accelerate our impact in cardiovascular intervention”....
...Tirzepatide is part of a new class of weight-loss drugs, known as GLP-1s, which includes Novo Nordisk’s Wegovy and Ozempic drugs, that are projected to expand to a $100bn market by the end of the decade,...
...Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage clinical trial, the pharmaceutical group said on Wednesday, adding to evidence that could encourage more...
...The group had a market value of $600mn, as of market close on Friday....
...Last year, Shockwave completed a $147mn acquisition of Neovasc, which produces a device to treat refractory angina, another type of heart defect....
...Aardvark Therapeutics, a US biotech group developing a weight loss pill, is planning to raise up to $200mn in an initial public offering as early as this summer, propelled by investor hype over anti-obesity...
...“We employ a consultancy to do our R&D claims for us because we haven’t got the time to fight the claims,” he said....
...A person in Texas has contracted the second known human case of H5N1 bird flu in the US, the Centers for Disease Control and Prevention said....
...Greencore did complete a £50mn share repurchase programme recently, but a person familiar with Oasis’s thinking described them as “really small”....
International Edition